Artificial intelligence (AI) continues to reshape the medical device industry. From diagnostic support tools and medical imaging software to Software as a Medical Device (SaMD), AI-enabled medical devices are becoming increasingly embedded in health care innovation.

At the same time, many companies are discovering that successful global medical device commercialization involves more than developing the technology itself and obtaining regulatory approval. As digital health businesses grow, questions surrounding technology protection, strategic partnerships, manufacturing structures, and intellectual property (IP) strategies are becoming increasingly important. Recent industry discussions have highlighted trade secret protection, Freedom to Operate (FTO), global IP planning, and cross-border commercialization as areas receiving growing attention from medical device companies.

What Is An AI-Enabled Medical Device, and Why Is the Market Growing So Quickly?

An AI-enabled medical device generally refers to a product that uses artificial intelligence or machine learning to analyze medical information, support clinical decision-making, or improve device functionality.

Examples of AI-enabled medical devices may include:

• AI-assisted diagnostic tools
• Medical imaging analysis software
• Physiology assessment platforms
• Treatment response monitoring solutions
• Software as a Medical Device (SaMD)

Recent patent activity suggests that AI-driven innovation continues to expand across several healthcare applications, particularly in diagnostic support, monitoring, and clinical workflow optimization.

How AI-Enabled Medical Device Growth Changes Commercialization and Intellectual Property Strategy

Investment and development activity in AI-enabled healthcare technologies continue to increase, and many companies are focused on accelerating innovation and commercialization.

However, growth often changes the questions companies need to ask themselves. As organizations scale, leadership teams often need to answer:

• How could global expansion affect our patent, trade secret, and regulatory strategies?
• Have we evaluated our Freedom to Operate (FTO) before expanding to new markets?
• Do we have an intellectual property strategy that supports our commercialization goals?

During the early stages, the primary focus may be product development and regulatory milestones. As organizations scale, attention often shifts toward manufacturing decisions, partnership structures, information sharing, and long-term commercialization planning. These business decisions can directly affect how medical technology and intellectual property are managed throughout the lifecycle of a product.

Why Commercializing AI-Enabled Medical Devices Creates New IP Challenges

As digital health companies move beyond development and into commercialization, they frequently begin working with a broader network of stakeholders.

As commercialization efforts expand, companies often begin working with a broader network of stakeholders, including:

• Manufacturing partners
• Technology collaborators
• Distributors
• Strategic investors
• International business partners

As more parties become involved, valuable technical information is often shared more broadly than originally anticipated. This can create new questions about ownership, confidentiality, and long-term technology protection.

Why Are Trade Secrets Receiving More Attention?

For many AI-enabled medical device companies, competitive advantage may come from more than the physical device itself.

Algorithms, data processing methodologies, internal workflows, and technical knowledge can all contribute significantly to product differentiation. In some cases, companies may choose not to publicly disclose certain technologies through patent filings and instead focus on protecting information internally as Trade Secrets. Recent industry commentary suggests that confidential information and technical know-how are becoming increasingly important components of broader IP strategy. 

As a result, companies are increasingly evaluating not only what they should protect, but how they should protect it.

How Are Companies Expanding Their IP and Legal Planning?

Developing technology and commercializing technology are not necessarily the same thing.

FTO generally refers to assessing whether a product can be brought to market without creating significant risk of infringing another party’s intellectual property rights.

This consideration can become particularly relevant in AI-enabled medical devices, where multiple technologies may be integrated into a single solution. As products become more sophisticated and enter larger markets, companies often seek greater visibility into potential IP risks before significant resources are committed to commercialization.

How Growth Often Creates Global IP Questions

Many companies begin by focusing on a single market.

As businesses expand, however, they often introduce:

• Global manufacturing relationships
• International distribution channels
• Cross-border partnerships
• Multi-market commercialization strategies

When operations extend across multiple jurisdictions, intellectual property considerations can become more complex. Industry commentary continues to emphasize the importance of aligning IP strategy with broader business and commercialization objectives, particularly as companies become more globally connected.

This is less about filing patents everywhere and more about understanding how business growth may create new technology protection challenges.

Global Commercialization Creates New Risks and New Opportunities

Modern medical device companies rarely operate in isolation.

As organizations scale, questions surrounding information sharing, technology transfer, supplier relationships, and international business operations often become increasingly relevant. Industry discussions frequently reference concerns involving reverse engineering, knowledge transfer, and information governance as companies expand beyond a single market or operating structure.

For AI-enabled businesses, where critical value may reside in software, data-processing methods, or technical expertise, these considerations can become important components of commercialization planning.

The Future of AI-Enabled Medical Device Commercialization and IP Strategy

The AI-enabled medical device sector is expected to remain an important area of innovation and growth for the foreseeable future.

As companies mature, however, commercialization challenges often extend beyond product development and regulatory approval. Questions involving Trade Secret protection, Freedom to Operate, global IP planning, and global commercialization are increasingly being discussed not simply as legal matters, but as business considerations tied directly to growth and long-term value creation.

For startups, growth-stage companies, and established medical device organizations alike, successful commercialization may require more than technical innovation alone. Increasingly, business, technology, and legal considerations appear to be converging, making early planning and cross-functional collaboration valuable components of a broader growth strategy.

Plan for What’s Next in AI-Enabled Medical Device Commercialization

Whether you are protecting proprietary algorithms as trade secrets, evaluating Freedom to Operate before entering a new market, or structuring cross-border partnerships that safeguard your most valuable know-how, early and coordinated planning can make the difference between scalable growth and avoidable risk. Ice Miller's Intellectual Property and Life Sciences teams help medical device and digital health companies align IP strategy with commercialization goals at every stage. Contact our team to get started.

This article is provided for general informational purposes only and does not constitute legal advice. The analysis herein is based on publicly available information and may not apply to all factual circumstances. Companies should seek specific legal counsel for advice tailored to their individual situations.